For out-of-pocket drugs like oral Wegovy, Novo Nordisk leverages telehealth platforms for distribution. This GTM strategy achieves rapid patient uptake, contrasting with slower, traditional models that rely on educating and detailing primary care physicians, reaching 300,000 UK patients in weeks.

Protagonist believes its oral IL-23 blocker will not just compete with existing injectables but will capture a new market. They target the over 50% of eligible patients who currently take no therapy due to a dislike of injections or the safety profiles of other oral options, thereby expanding the total addressable market.

The introduction of oral GLP-1 medications is proving to be a market expansion strategy, not a cannibalization one. Data shows that the majority of patients starting on oral versions are new to the GLP-1 category entirely, indicating the new form factor overcomes a key barrier to adoption.

Novo priced the maintenance dose of its oral Wegovy pill far lower than anticipated. This aggressive strategy, costing less than the average U.S. monthly grocery bill (~$400), is a direct attempt to regain momentum from rival Eli Lilly and expand the self-pay market before more oral competitors launch.

The transition to oral GLP-1 therapies is a significant market expander, not just a convenience upgrade. Nearly 80% of patients starting oral medications are new to the drug category, indicating a substantial increase in the addressable patient pool rather than simple conversion of existing users.

Beyond converting patients from existing injectable therapies, the company's core growth strategy for its oral IL-23 drug is to capture the 50%+ of eligible patients who currently refuse treatment altogether because they dislike injections. This transforms the strategy from market share capture to market creation.

While analysts widely predicted Eli Lilly's GLP-1 pill would dominate the oral obesity market, early launch data shows Novo Nordisk's Wegovy pill is having the "strongest ever GLP-1 volume launch." This swift market reversal highlights the unpredictability of drug launches, even in highly anticipated categories.

Eli Lilly's oral GLP-1 is proving to be a market expander, not just a cannibalizer of injectables. An overwhelming 80% of its users are new to the GLP-1 class, driven by an aggressive direct-to-consumer (DTC) telehealth strategy. This signals a vast, untapped patient population for oral obesity treatments.

Contrary to the common view that generics immediately cannibalize a brand-name drug's volume, Novo Nordisk's CFO observed that upon generic entry in some markets, they held their volume while the generics primarily expanded the total market, alongside driving prices down.